Biopharma M&A booms in 2014, with GSK-Novartis swap just one example
April 25, 2014 at 15:56 PM EDT
Clearly, merger and acquisition activity in the biopharmaceutical industry is alive and well. The big news for that industry in Research Triangle Park this week was the asset swap between GlaxoSmithKline (NYSE: GSK) and Novartis (NYSE: NVS) that also included Eli Lilly (NYSE: LLY) as a third partner...
